We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. For further information please read our cookie policy.
Cortoss material was developed to provide an ideal bone augmentation solution for treatment of vertebral compression fractures (VCFs).
Cortoss is an advanced, injectable, synthetic, non-resorbable biomaterial which mimics the mechanical properties of cortical (weightbearing) bone1. It has been clinically proven to match the safety and effectiveness of Polymethylmethacrylate (PMMA) for vertebral augmentation.2
Flow and fill: properties improve short-term pain and long-term function2
Safety: low incidence of adjacent fractures2; minimal exotherm3 and monomer release4
Control: procedural flexibility with mix-on-demand and start/stop delivery5
Robust compilation of clinical data2,6,7
Multi-center clinical trials provide the proof:
Warning/adverse events
Serious adverse events, some with fatal outcome, associated with the use of bone cements for vertebroplasty, kyphoplasty and sacroplasty include myocardial infarction, cardiac arrest, cerebrovascular accident, pulmonary embolism, and cardiac embolism. Although it is rare, some adverse events have been known to occur up to one year post-operatively. Additional risks exist with the use of bone cement. Please see the IFU for a complete list of potential risks.
1000-025-852 Rev None